Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI response claim about increased malignancy risk and teratogenic/fetal harm risk, including the relevant contraindications (current malignancy; pregnancy; reproductive potential without effective contraception), is fully supported by the provided FDA-approved MAVENCLAD prescribing information (boxed warning, Sections 4, 5.1, and 5.2).
Category Scores
Accurate Statements
MAVENCLAD increases malignancy risk and is contraindicated in patients with current malignancy.
BOXED WARNING (MALIGNANCIES AND RISK OF TERATOGENICITY); SECTION 5.1 (Malignancies); SECTION 4 (Contraindications).
MAVENCLAD has teratogenic/fetal harm risk and is contraindicated in pregnant patients or in those of reproductive potential who do not plan to use effective contraception.
BOXED WARNING (Risk of Teratogenicity); SECTION 5.2 (Risk of Teratogenicity); SECTION 4 (Contraindications); SECTIONS 8.1 and 8.3 (Pregnancy and Contraception/Pregnancy Testing).
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The evaluated statements are consistent with labeled boxed warning/contraindications and do not introduce unsupported claims; no safety-relevant omissions were identified for the specific claim scope provided.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement